BREAKING: President Trump's drugmaker deals may save the economy $529 billion over 10 years, according

President Trump's pharmaceutical agreements could potentially inject $529 billion into the U.S. economy over the next decade, a recent White House analysis reveals. This report, obtained by the Associated Press, highlights several key points. First, the proposed drug pricing strategies aim to reduce healthcare costs significantly, benefiting both consumers and the industry. Second, the administration's approach seeks to balance innovation with affordability, encouraging drug manufacturers to invest in new treatments while keeping prices in check. Third, the anticipated savings could lead to lower insurance premiums and out-of-pocket costs for millions of Americans. Lastly, this economic boost might support broader fiscal stability, potentially impacting other policy areas. As stakeholders digest these findings, the implications of these deals continue to spark debate across political and healthcare sectors.